



20            abombin93@gmail.com

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

## 38 **ABSTRACT**

39           Obesity is an increasing global health concern and is associated with a broad range of  
40 morbidities. The gut microbiota are increasingly recognized as important contributors to obesity  
41 and cardiometabolic health. This study aimed to characterize oral and gut microbial  
42 communities, and evaluate host:microbiota interactions between clinical obesity classifications.  
43 We performed 16S rDNA sequencing on fecal and salivary samples, global metabolomics  
44 profiling on plasma and stool samples, and dietary profiling in 135 healthy individuals. We  
45 grouped individuals by obesity status, based on body mass index (BMI), including lean (BMI 18-  
46 24.9), overweight (BMI 25-29.9), or obese (BMI  $\geq 30$ ). We analyzed differences in microbiome  
47 composition, community inter-relationships, and predicted microbial function by obesity status.  
48 We found that salivary bacterial communities of lean and obese individuals were  
49 compositionally and phylogenetically distinct. An increase in obesity status was positively  
50 associated with strong correlations between bacterial taxa, particularly with bacterial groups  
51 implicated in metabolic disorders including *Fretibacterium*, and *Tannerella*. Consumption of  
52 sweeteners, especially xylitol, significantly influenced compositional and phylogenetic  
53 diversities of salivary and fecal bacterial communities. In addition, obesity groups exhibited  
54 differences in predicted bacterial metabolic activity, which was correlated with host's metabolite  
55 concentrations. Overall, obesity was associated with distinct changes in bacterial community  
56 dynamics, particularly in saliva. Consideration of microbiome community structure, and  
57 inclusion of salivary samples may improve our ability to understand pathways linking microbiota  
58 to obesity and cardiometabolic disease.

## 59 **IMPORTANCE**

60           Obesity is a worldwide epidemic that is associated with a wide range of health issues.  
61   Microbiota were shown to influence metabolism and obesity development. Our study aimed to  
62   evaluate the interactions between obesity, salivary and fecal microbiota, and metabolite  
63   concentrations in healthy individuals. The oral bacterial community was more impacted by the  
64   obesity status of the host than fecal microbiota. Consistently for oral and fecal microbiota, the  
65   number of strong interactions between bacteria increased with the increase in the obesity status.  
66   Several predicted microbial metabolic pathways that were shown to be associated with metabolic  
67   health were uniquely enriched between obesity groups. In addition, these metabolic pathways  
68   were correlated with plasma and stool metabolites. Our results suggest that oral microbiota might  
69   better reflect the obesity status of the host than fecal microbiota, and that correlations between  
70   microbial taxa are altered during obesity.

71

## 72   **INTRODUCTION**

73           Obesity is a growing worldwide epidemic and is linked to a range of health issues  
74   including hypertension, type 2 diabetes, asthma, coronary heart disease, Alzheimer’s disease and  
75   cancer [1-5]. Known risk factors include imbalances between calorie intake and expenditure,  
76   genetics, stress, and disruptions in the endocrine system [1, 6]; however much remains unknown.  
77   Better characterization of mechanisms predisposing to obesity could enable novel prevention and  
78   treatment strategies.

79   The composition of an individual’s microbiota is increasingly being recognized as a contributor  
80   to obesity risk [7-9]. Microbiota can influence the host’s metabolic phenotype both by directly  
81   affecting energy and nutrient availability [10-14], and through modulation of signaling pathways

82 [15-22]. Previous studies suggested that the fecal symbiotic bacterial community of obese  
83 individuals is less diverse than that of lean individuals [8, 23]. In addition, the abundance of  
84 several bacterial taxa including *Lactobacillus*, *Pervotella*, *Alistipes*, *Akkermansia*, and others  
85 vary with obesity status [7, 9]. Salivary microbiota of lean and obese individuals also differ in  
86 diversity and composition [9, 24-27]. Abundance of several salivary bacterial taxa including  
87 *Campylobacter*, *Aggregatibacter*, and *Veillonella* was reported to be positively associated with  
88 obesity [28-30]. Higher abundances of Bacteroidetes, Spirochaetes, and Firmicutes were  
89 observed in lean individuals [9, 31, 32]. However, data are contradictory, even for rather  
90 abundant bacteria taxa. For example, the abundance of intestinal *Lactobacillus* was reported to  
91 be both positively and negatively associated with obesity [7, 33-35]. These discrepancies may be  
92 due in part to complex interactions between microbial community members, where metabolic  
93 activity of individual bacterial taxa can vary based on the activity of other microbes in the  
94 community [36-39]. Consideration of interactions between members of microbiota might be  
95 essential to improve identification of bacterial mechanisms underlying obesity.

96 We hypothesized that the presence of obesity, in the absence of known disease, would  
97 associate with differences in microbiome composition and function. We further hypothesized  
98 that community structure and bacterial inter-relationships would differ by obesity status. We  
99 evaluated the differences in compositional and phylogenetic diversity of salivary and fecal  
100 microbiota between obesity groups in a well-characterized sample of healthy individuals. We  
101 examined interactions between bacterial taxa based on obesity status of the host, and showed  
102 that predicted bacterial metabolic activity varies between obesity groups and is correlated with  
103 intestinal and circulating metabolite concentrations.

## 104 MATERIALS AND METHODS

105           **Study population.**

106   We analyzed data from the ABO Study (n=135) as described previously [40-42]. Briefly, healthy  
107   non-pregnant and non-lactating women and men were recruited to a cross-sectional study.  
108   Participants completed dietary profiling (validated 3-day food records, and DHQ II food  
109   frequency questionnaires [FFQ]), and provided stool, saliva, and blood samples. Height and  
110   weight were measured at the study visit. Individuals were classified based on body mass index  
111   (BMI, weight (kg)/height (m)-squared), including lean (BMI 18-24.9; fecal samples n=76, saliva  
112   samples n=49), overweight (BMI 25-29.9; fecal samples n=34, saliva samples n=19), or obese  
113   (BMI  $\geq$ 30, fecal samples n=25, saliva samples n=16), to explore differences in composition and  
114   function of microbiota by obesity. All participants provided written informed consent. The study  
115   was approved by the Institutional Review Boards of the University of Pennsylvania and  
116   Vanderbilt University.

117           **Sample Profiling.**

118   As we have previously described, 16S rDNA sequencing of the bacterial V4 fragment was  
119   performed on Illumina MiSeq platform using 135 fecal and 85 saliva samples to identify  
120   bacterial community composition [42]. Global metabolomics profiling of fecal and plasma  
121   samples, from a subset of individuals (n=75) was performed at Metabolon (Metabolon Inc.,  
122   Morrisville, NC, United States).

123           **Pre-analysis processing.**

124           Sequences alignment and normalization. Pre-analysis processing of 16SrRNA reads was  
125   performed with R v4.0.2 [43]. Demultiplexed sequences were filtered, forward and reverse reads  
126   were merged, and resulted sequences were assigned to amplicon sequence variants (ASVs), with

127 the default settings of DADA2 pipeline v1.18.0 [44]. Chimeric sequences were also removed  
128 with the dada2 package v1.18.0 [44]. Sequence variants were assigned taxonomy with dada2  
129 and SILVA v138.1 database [44, 45]. ASVs counts were normalized with cumulative sum  
130 scaling method implemented in the metagenomeSeq v1.32.0 package [46]. In the salivary  
131 samples, we identified 1,932 ASVs that belonged to 12 phyla, 19 classes, 44 orders, 70 families,  
132 134 genera, and 229 bacterial species. In our fecal samples, we identified 5,000 ASVs that  
133 belonged to 16 phyla, 26 classes, 55 orders, 86 families, 270 genera, and 338 bacterial species.

134 Alpha diversity. Normalized ASVs counts were used to calculate species richness,  
135 Shannon, and Gini–Simpson alpha diversity indices with the vegan v2.5.7 package [47]. Beta  
136 diversity. Bray-Curtis distances were calculated with vegan v2.5.7 [47]. Unrooted neighbor-  
137 joining tree was computed with the ape package v5.5 [48]. The tree was optimized based on  
138 generalized time-reversible model implemented in the phangorn v2.5.5 package [49, 50]. Lastly,  
139 weighted and unweighted Unifrac distances between each sample were calculated with the  
140 phyloseq v1.30.0 package [51].

141 Functional potential of the bacterial communities was predicted with PICRUSt2  
142 according with the default pipeline [52]. Predictions were made for Enzyme Commission  
143 numbers (EC), Kyoto Encyclopedia of Genes and Genomes orthologs (KO), and MetaCyc  
144 pathways [52-55]. In accordance with PICRUSt2 authors' recommendations, the resulting data  
145 were transformed with centered-log ratio transformation implemented in the ALDEx2 v1.24.0  
146 package [56].

147 **Statistical Analysis.**

148           Statistical analysis and data visualization was done with R v3.6.1 [43]. Beta diversity  
149 distances between obesity groups were compared with pairwise permutational multivariate  
150 analysis of variance, based on the vegan package v2.5.7 [47]. The difference in alpha diversity  
151 measurements was evaluated with Wilcoxon signed-rank test, implemented in the rstatix v0.7.0  
152 package [57]. In order to evaluate if the obesity groups can be classified based on abundance of  
153 bacterial taxa and inferred functional abundances (based on EC, KO, and MetaCyc  
154 classification), we used linear discriminant analysis, implemented in in the MASS package v7.3-  
155 51.4 [58]. In addition, we repeated linear discriminant analysis using only the 15 most abundant  
156 bacterial taxa, in order to evaluate if the dominant bacterial taxa were sufficient for  
157 discrimination of the communities, with the obesity status. The results were visualized by  
158 plotting the first and second linear discriminants, with the ggplot2 v3.2.1 and the ggpubr v0.4.0  
159 packages [59, 60]. The difference in abundances of bacterial taxa and predicted ECs, KOs, and  
160 MetaCyc pathways, between obesity groups was evaluated with a pairwise t-test function,  
161 implemented in R v3.6.1 [43]. The correlations between abundances of bacterial taxa were  
162 calculated with Spearman's rank correlation test, included in the Hmisc v4.5.0 package [61].  
163 Resulted correlation matrices were used to construct network plots, using the corrr v0.4.3  
164 package [62]. In addition, the absolute values of correlation coefficients were compared between  
165 obesity groups with a pairwise Wilcoxon signed-rank test, implemented in the rstatix v.7.0  
166 package [57]. The influence of 133 recently consumed (from 3-day food records) and 185  
167 habitually consumed (from FFQ) nutrients on beta diversity distances was evaluated with  
168 permutational multivariate analysis of variance using a quadratic model [47]. The quadratic  
169 model was used as most living organisms, including bacteria have an optimal range of  
170 environmental conditions rather than a linear relationship [63-65].



171 For enrichment analysis, we calculated the mean abundance of each KEGG ortholog for  
172 obesity groups and used them as input for MicrobiomeAnalyst (2021-07-01) shotgun data  
173 profiling tool, with the default settings [66]. False discovery rate (FDR) *P*-values were adjusted  
174 using the Benjamini–Hochberg correction, implemented in rstatix v0.7.0 package [57]. We note  
175 that usage of any particular FDR threshold is ambiguous and often varies between microbiome  
176 studies; weaker correlations that fail to hold up to *p* adjustment methods often have biological  
177 relevance. Premature rejection of associations falling below conservative *p*-value thresholds may  
178 lead to loss of biologically meaningful data. [67-72]. For this reason, statistical results below  
179 0.05 *p*-value threshold were considered to be significant. However, taking into account the  
180 difference in opinions and for the readers' convenience, we report both unadjusted and FDR-  
181 adjusted *p*-values in supplementary data.

182

## 183 **RESULTS**

184 **Lean, overweight and obese individuals can be separated into distinct groups based**  
185 **on their oral and intestinal microbiota.**

186 Evaluating beta diversity distances, we observed that salivary microbiota communities of  
187 obese and lean individuals were significantly different as measured with Bray-Curtis and  
188 Weighted Unifrac distances (**Supplement Table 1**). Based on linear discriminant analysis (non-  
189 overlapping confidence ellipses), obesity classes were separated by the abundances of bacterial  
190 ASVs (**Fig. 1A**). Obesity groups were also clearly characterized based on abundance of  
191 microbial species, genera, families, and orders but weaker based on classes and phyla  
192 (**Supplement Figure 1**).

193 In fecal samples, we did not observe a significant difference in beta diversity distances  
194 between any of the obesity groups (**Supplement Table 1**). However, based on a linear  
195 discriminant analysis, obesity groups could be classified based on abundance of bacterial ASVs  
196 (**Fig. 1B**). Obesity groups were also clearly characterized based on abundance of bacterial  
197 species, genera, families, and orders but weaker at class and phylum ranks (**Supplemental**  
198 **Figure 2**). We did not observe any significant differences in alpha diversity indices between  
199 obesity groups in saliva or feces (**Supplement Table 2**).

### 200 **Obesity status influences the abundance of individual bacterial taxa**

201 In saliva, we observed that abundances of Campylobacterota, Firmicutes, and  
202 Spirochaetota were significantly different between obesity groups at the phylum rank. Obesity  
203 groups were significantly different in the abundances of 5 bacterial classes, 10 orders, 17  
204 families, 33 genera, 52 species, and 409 individual ASVs (**Supplement Table 3A**). Across all  
205 taxonomic ranks, obese and lean individuals had the highest number of taxa that were  
206 significantly different in their abundances (**Supplement Table 3A**). We evaluated which of the  
207 15 most abundant bacteria taxa were the most influential for defining each of the obesity groups  
208 with a linear discriminant analysis. At the genera taxonomic rank, *Campylobacter*, *Veillonella*,  
209 *Aggregatibacter*, and *Prevotella* defined the obese group (**Fig. 2**). Although lean and overweight  
210 groups were not distinct from each other, *Actinomyces* and *Haemophilus* were characteristic for  
211 overweight group (**Fig. 2**). Overall, we note that the 15 most abundant bacteria taxa contribute  
212 only modestly to discrimination of obesity groups (**Supplemental Fig. 3**).

213 In feces, at the phylum rank, only abundance of Fusobacteriota was significantly different  
214 between overweight and lean groups. Obesity groups were significantly different in the  
215 abundances of 2 bacterial classes, 8 orders, 10 families, 35 genera, 45 species, and 690 individual

216 ASVs (**Supplement Table 3B**). The highest number of significant differences between groups  
217 varied with taxonomic rank but was always between lean and one of the overweight/obese  
218 groups. Linear discriminant analysis indicated that at the genus taxonomic rank *Agathobacter*  
219 and *Parabacteroides* were influential in discriminating obese from lean groups (**Fig. 2**).  
220 Although lean and overweight groups were not clearly separated, lean group was primarily  
221 characterized by *Blautia* and *Ruminococcus* (**Fig. 2**). Similar to what we observed in salivary  
222 samples, the most abundant fecal bacteria taxa were not the most influential variables for  
223 discriminating samples based on obesity status (**Supplemental Figure 4**).

224

#### 225 **The number of strong correlations between bacterial taxa vary by obesity status.**

226 We hypothesized that microbial community inter-relationships, as evidenced by  
227 correlations between taxa, would differ by obesity status. We assessed the number of strong  
228 correlations ( $\geq |0.7|$ ) between abundances of microbial taxa in saliva and stool samples by  
229 obesity group and found evidence for increasing inter-dependence in the setting of obesity (**Fig**  
230 **3**). Among microbiota genera in saliva, there were 67 strong correlations in the obese group, 32  
231 in the overweight, and only 5 strong correlations in the lean group. The absolute means of  
232 correlation coefficients were significantly different between all groups, and this observed pattern  
233 remained across all taxonomic ranks (**Supplement Table 4**). We observed a similar pattern in  
234 fecal samples, with 52 strong correlations between microbiota genera in the obese group, 20 in  
235 the overweight group, and only 8 in the lean group. The absolute values of the correlation  
236 coefficients, for abundances of the bacterial taxa were significantly different between all obesity  
237 groups. Obese individuals had more strong correlations between bacterial taxa than lean

238 individuals across all phylogenetic ranks except phylum, at which no group had strong inter-  
239 bacterial correlations. (**Supplement Table 4**).

#### 240 **Nutritional Factors Influencing Bacterial Communities.**

241 We examined the relationships between dietary variables and the overall bacterial  
242 community, to identify influential nutrients from recent (3-day food records) and habitual (food  
243 frequency questionnaire) consumption. We applied Bray-Curtis, weighted Unifrac, and  
244 unweighted Unifrac distances, and assessed both linear and quadratic relationships. For recently-  
245 consumed nutrient, xylitol and pectins had significant linear relationships across all 3 methods,  
246 while inositol, glucose and omega-3 polyunsaturated fatty acids approached significance for  
247 quadratic relationships across all 3 methods (**Supplement Table 5**). For habitually-consumed  
248 nutrients, no nutrients displayed consistent linear relationships across all methods, while for  
249 quadratic relationships, sorbitol and pinitol, as well as dairy cheese and yogurt were consistently  
250 associated (**Supplement Table 6**). In the fecal bacterial community, recently-consumed pectins,  
251 folate, and fiber had consistent significant linear relationships, while oxalic acid, formononetin,  
252 biochanin A, and the ratio of polyunsaturated to saturated fat had consistent quadratic  
253 relationships (**Supplement Table 5**). For habitually-consumed foods, there were consistent  
254 linear relationships with cheese and vegetables, in addition to vegetable-derived nutrients (beta  
255 carotene, oxalic acid, Vitamin K). Significant quadratic relationships were observed for grains  
256 and processed meats, in addition to xylitol, caffeine, sodium and potassium (**Supplement Table**  
257 **6**).

258 **Analysis of inferred metabolic pathways reveals enrichment in 2-oxocarboxylic acid**  
259 **metabolism in lean individuals in oral and intestinal microbiota**

260 We hypothesized that functional activity of microbiota, as predicted using PICRUSt2,  
261 would differ by obesity status. We assessed differences in inferred function between obesity  
262 groups, and found that obesity served as a good classifier for enzyme counts (ECs), KEGG  
263 orthologs (KOs), and MetaCyc pathways abundances in saliva (Fig. 4). There were 969  
264 significant differences in ECs, 3,915 in KOs and, 177 significant differences in the abundance of  
265 MetaCyc pathways across all groups (**Supplement Table 7**). In all cases, lean and obese  
266 individuals had the highest number of differences. 2-oxocarboxylic acid metabolism, terpenoid-  
267 quinone biosynthesis, and D-glutamine and D-glutamate metabolism KEGG pathways were  
268 enriched in lean individuals but not in obese group (**Supplement Table 8**). The obese group was  
269 uniquely enriched in fluorobenzoate, sulfur, and several amino acid metabolic pathways.

270 Similarly, obesity groups could be characterized based on abundance of MetaCyc  
271 pathways, KOs, and ECs in fecal samples (Fig. 4). We observed 128 significant differences  
272 between the obesity groups in ECs, 391 in KOs, and 19 in MetaCyc pathways (**Supplement**  
273 **Table 7**), spread across lean, overweight and obese groups. The lean group was uniquely  
274 enriched in 2-oxocarboxylic acid metabolism, D-glutamine and D-glutamate metabolism, and  
275 pentose and glucuronate interconversions, when compared with obese group. The obese group  
276 was enriched in C5-branched dibasic acid, lipoic acid, and one-carbon KEGG metabolic  
277 pathways (**Supplement Table 8**).

278

279 **Abundance of inferred bacterial metabolic enzymes/pathways influences host's**  
280 **metabolites' concentrations.**

281 We were interested in whether predicted functional activity would associate with  
282 measured metabolic activity, as assessed by metabolomic profiling of plasma and stool. We  
283 observed high numbers of correlations with predicted saliva microbial activity across all 3  
284 databases (EC: 78,635 with plasma, 82,722 with stool; KO: 249,473 plasma, 263,616 stool;  
285 MetaCyc: 15,633 plasma, 17,915 stool). The highest number of correlations was observed with  
286 valerate and isoeugenol sulfate in plasma samples and with inosine in stool samples  
287 (**Supplement Table 9**). We similarly observed high numbers of correlations between predicted  
288 stool microbial activity and metabolites (EC: 92,852 with plasma, 109,830 with stool; KO:  
289 299,557 plasma, 332,789 stool; MetaCyc: 18,179 plasma, 17,728 stool). The highest number of  
290 correlations was observed with 1-palmitoyl-GPE and CMPF in plasma samples and steviol in  
291 stool samples (**Supplement Table 9**).

## 292 **DISCUSSION**

293 Obesity has been linked to alterations in microbiota, however the relative importance of  
294 gut and oral microbiota is unclear. We aimed to identify microbial signatures of obesity using  
295 both stool and salivary samples in healthy individuals classified as normal weight, overweight or  
296 obese based on their BMI. We observed that obesity status was associated with differences in  
297 bacterial community composition and shifts in inter-microbial relations that were especially  
298 evident in the salivary bacterial community. Although salivary and fecal microbiota were largely  
299 impacted by different nutrients, dietary sweeteners were associated with both composition and  
300 phylogenetic diversity of both the oral and gut bacterial communities. In addition, samples from  
301 obese and lean individuals were enriched in several unique metabolic pathways, inferred activity  
302 of which was correlated with plasma and stool metabolite concentrations.

303 **Obesity influences microbial community composition, especially in saliva.**

304 In agreement with published research, we observed that oral bacterial community  
305 composition was distinct between lean and obese individuals [24-27]. In our work, we also  
306 observed that the difference in salivary bacterial composition between obese and lean individuals  
307 extends to phylogenetic diversity measurements. Consistent with previous research, we also  
308 observed some differences in gut bacterial communities between obese and lean groups, however  
309 in our work the differences were not supported by Bray-Curtis or weighted Unifrac distances  
310 [73, 74]. Our results suggest that at the level of the whole community, salivary microbiota  
311 composition better reflects the difference in obesity status than fecal microbiota.

312 With the analysis restricted to the dominant bacterial taxa, we observed a strong influence  
313 of *Campylobacter*, *Aggregatibacter*, *Veillonella*, and *Prevotella* on characterizing the obese  
314 group in salivary samples. Interestingly, all of these bacterial genera have been shown to be  
315 correlated not only with obesity but also with oral diseases, especially periodontitis [28-30, 75-  
316 77]. Considering the whole bacterial community (abundance >20 reads), we observed that some  
317 of the bacteria taxa with lower abundance had a stronger effect on differentiation of the obese  
318 group than dominant bacteria, including *Shuttleworthia* at the genus rank and Mycoplasmataceae  
319 at the family rank that were also significantly more abundant in the obese group. Previous studies  
320 identified a correlation between Mycoplasmataceae and obesity [78, 79]. Although to the best of  
321 our knowledge, no previous works associated *Shuttleworthia* with obesity in humans, it was  
322 associated with obesity and elevated weight in model organisms [80-82]. In addition, similar to  
323 what we observed with the dominant bacteria taxa, *Shuttleworthia* and Mycoplasmataceae are  
324 associated with periodontitis [83, 84].

325 In the fecal samples, the dominant bacterial genera that characterized the obese group  
326 were *Agathobacter* and *Parabacteroides*. *Agathobacter* and *Parabacteroides* were shown to be

327 associated with metabolic disorders in humans and a murine model [85-88]. Similar to what we  
328 observed in the saliva samples, several less abundant bacterial taxa that were previously  
329 associated with obesity, including *Mitsuokella* and *Neisseria*, at the genus rank and  
330 Fusobacteriaceae and Gemellaceae, at the family rank, produced more impact on separation of  
331 obese and lean categories than dominant bacterial taxa [73, 89-92]. Proportionally to all  
332 identified taxa, more organisms were significantly different in abundance between lean and  
333 obese groups in saliva samples, when compared with fecal samples, which might suggest that  
334 sampling oral microbiota may be more informative in identifying microbial biomarkers of  
335 obesity. Given the relative ease of collection of saliva as compared with stool, this could  
336 facilitate increased accessibility for research into the microbial contributors to obesity and  
337 cardiometabolic disease; however this remains to be confirmed in independent studies.

338 **Number of strong correlations between bacterial taxa increases with the obesity**  
339 **status.**

340 In saliva samples, bacterial taxa exhibited the highest inter-microbial connectivity (strong  
341 correlations  $\geq 0.7$ ) in obese individuals. In the obese group, the highest connectivity was  
342 observed for *Fretibacterium* (eight connections), *F0058* (seven connections), *Mycoplasma*  
343 (seven connections), and *Tannerella* (seven connections). Several of these genera, including  
344 *Fretibacterium*, *F0058*, and *Tannerella* were shown to be correlated with metabolic disorders  
345 [31, 93-96]. In addition, all of the most connected bacterial taxa were associated with  
346 periodontitis [83, 94, 97, 98]. In the lean group, the most connected bacteria exhibited less strong  
347 connections than in obese group and were *Atopobium* (three connections), *Megasphaera* (two  
348 connections), and *Prevotella 7* (two connections). Abundance of *Atopobium* was shown to be  
349 reduced in obese individuals [99]. Previous research indicated that the abundance of



350 *Megasphaera* might increase after anti-obesity treatments [100, 101]. *Prevotella* was shown to  
351 be associated with plant rich diet and increase in abundance after antidiabetic treatment, however  
352 the genus is very diverse [102-104].

353 In the fecal samples, the most connected bacterial genera identified in obese group were  
354 *Christensenellaceae R7* group (eight connections) and *Ruminococcaceae UCG-005* (five  
355 connections). *Christensenellaceae R7* and *Ruminococcaceae UCG-005* were shown to be  
356 associated with plasma lipoproteins and triglycerides [105]. *Ruminococcaceae UCG-005* was  
357 also shown to be positively correlated with body weight and weight gain in a swine model [106,  
358 107]. In addition, several bacterial taxa previously implicated in metabolic disorders, including  
359 *Actinomyces*, *Ruminiclostridium*, and *Lachnospiraceae* exhibited strong inter-bacterial  
360 correlations in the obese but not in the lean group [74, 108-110]. The most connected genus in  
361 lean individuals was *Ruminococcaceae NK4A214* (three connections). Previous research  
362 identified a negative correlation between *Ruminococcaceae NK4A214* and high fat diet and  
363 hypertension [111, 112]. However, *Christensenellaceae R-7* group and *Ruminococcaceae UCG-*  
364 *005* were also among few genera (total three) that had more than one strong correlation in lean  
365 individuals.

366 The impact of the higher degree of microbial interconnectivity observed in obese  
367 individuals is unclear but may represent a shift from relative independence of bacterial taxa to a  
368 state more reliant on mutualistic relationships. Obesity is often associated with several  
369 physiological and environmental conditions that have the potential to act as stressors for the  
370 microbial community, including micronutrient deficiency, increased levels of reactive oxygen  
371 species, and increase in c-reactive protein concentrations and inflammatory response in the host  
372 [113-116]. In accordance with the stress gradient hypothesis, several studies demonstrated that

373 presence of environmental stressors often increases positive facilitation between microbial taxa  
374 in the community [117-120]. In addition, it was demonstrated that nutritional stress could  
375 increase the number of connections, in a co-occurrence network of the microbiota members  
376 [121]. In agreement with these observations, we found that in the obese individuals, almost all  
377 of the strong inter-microbial correlations were positive.

378 **Sweeteners and other nutrients influence compositional and phylogenetic diversity**  
379 **of salivary and fecal bacterial communities.**

380 We observed that recently and habitually consumed nutrients influenced bacterial  
381 communities. For salivary samples, recently consumed nutrients influenced bacterial community  
382 more than habitually consumed nutrients, for both compositional and phylogenetic beta diversity  
383 distances. Sugars and sugar alcohols, especially xylitol, mannitol, sorbitol, and pectin were  
384 especially influential factors impacting the bacterial community, based on compositional and  
385 phylogenetic diversity measurements. Interestingly, all of the listed compounds with the  
386 exception of pectin are used as sweeteners [122, 123]. Although the effect of sweeteners on gut  
387 microbiota was extensively shown in humans and animal models, the studies on oral bacteria  
388 community are limited [124, 125]. To the best of our knowledge, this work is the first report on  
389 the correlation between dietary sweeteners and phylogenetic diversity of the human's salivary  
390 bacterial community.

391 Fecal microbiota community was consistently more influenced by habitual nutrient  
392 consumption than recently consumed nutrients, which might suggest a more stable microbial  
393 community. Similar to the saliva samples, consumption of xylitol and pectin influenced  
394 compositional and phylogenetic diversity of fecal microbiota. Consumption of sweeteners,  
395 including xylitol was reported to influence intestinal bacterial community composition [124].

396 Pectin consumption was also shown to be correlated with compositional changes in the intestinal  
397 microbiota [126, 127]. In our study, compositional and phylogenetic measurements of the fecal  
398 microbiota were also consistently influenced by consumption of vegetables and plant-derived  
399 compounds including fiber, oxalic acid, formononetin, and daidzein. Consumption of fiber,  
400 formononetin, and daidzein was show to have microbiota-mediated beneficial effects on host's  
401 metabolic health [128, 129] In addition, habitual consumption of cholesterol and fatty acids also  
402 produced a significant effect on compositional and phylogenetic diversity distances of the fecal  
403 microbiota in our study.

404 **Bacterial communities of obesity groups are associated with enrichment in predicted**  
405 **metabolic pathways, which are correlated with host's metabolite concentrations.**

406 In both saliva and fecal samples, microbiota of the lean individuals were enriched in 2-  
407 oxocarboxylic acid metabolism and D-glutamine and D-glutamate metabolism, based on  
408 functional prediction. 2-Oxocarboxylic acid metabolism is involved in ornithine and lysine  
409 biosynthesis, supplementation of which were shown to have a potential for improving metabolic  
410 health [130-132]. D-Glutamine concentrations were shown to be decreased in obese individuals  
411 and glutamine supplementation may alleviate obesity symptoms [133, 134]. Metabolic pathways  
412 enriched in the microbiota of obese individuals included one-carbon metabolism, which was  
413 previously shown to contribute to the development of obesity[135]. In addition, steatosis was  
414 shown to be associated with one carbon metabolism's gene expression [136]. Enrichment in  
415 other pathways such as lipoic acid metabolism and degradation of valine, leucine, and isoleucine  
416 might be a response to increase in oxidative stress and branched-chain amino acids  
417 concentrations, often associated with obesity [137-139].

418 Multiple host's metabolites were significantly correlated with abundance of KOs  
419 involved in enriched pathways. For example, the abundance of KOs, predicted in salivary  
420 samples and involved in 2-oxocarboxylic acid metabolism influenced the concentration of 435  
421 plasma and 326 stool metabolites. Alpha-ketobutyrate was shown to be a biomarker of insulin  
422 resistance and glucose intolerance and in our study exhibited a negative correlation with more  
423 than half of the 2-oxocarboxylic acid metabolism pathway's KOs, predicted from saliva samples  
424 [140, 141]. In addition, KOs involved in 2-oxocarboxylic acid metabolism were correlated with  
425 adenosine and steviol in stool samples, both of which were shown to be beneficial for patients  
426 with metabolic disorders [142, 143].

427 Our study had considerable strengths, including availability of salivary and fecal  
428 microbial profiling, in addition to metabolic phenotyping, in a robust sample size. There were  
429 also some limitations inherent in all microbiome projects that are based on 16S rRNA  
430 sequencing. Namely, the necessity of choosing a specific segment of the gene, sequence filtering  
431 methods, reference database for taxonomic identification, and even normalization methods are  
432 all known to cause a degree of bias between studies. In addition, results presented in this study are  
433 largely based on relative abundances of the identified microbial taxa and therefore might not be  
434 interpreted as causative. Therefore, future studies would be necessary to demonstrate the  
435 directions of interactions between the host and its oral and intestinal microbiota.

## 436 **CONCLUSIONS**

437 In this study we identified differences in salivary and fecal symbiotic bacterial  
438 communities based on obesity status, in a population of otherwise healthy individuals. Our  
439 results suggest that inter-correlations between bacterial taxa are altered in the setting of obesity  
440 and suggest distinct differences in community dynamics at increasing levels of obesity.

441 Consideration of microbial community correlation structure might be more informative than  
442 measurement of relative abundances of bacteria taxa or diversity measurements alone. In  
443 addition, across multiple comparisons, salivary microbiota provided a more distinct pattern of  
444 differentiation between obese and lean individuals, than fecal microbiota. Previous studies have  
445 primarily focused on analysis of gut microbiota in obesity, however our data suggest that  
446 sampling oral microbiota might be a better choice in search of the bacterial biomarkers  
447 associated with obesity.

448

#### 449 **Acknowledgements**

450 This work was supported by funding from NIH R01 HL142856, and the Layton Family  
451 Fund.

452

## REFERENCES

- 453 1. Seganfredo, F., et al., *Weight-loss interventions and gut microbiota changes in overweight and*  
454 *obese patients: a systematic review*. Obesity Reviews, 2017.
- 455 2. Wahba, I.M. and R.H. Mak, *Obesity and obesity-initiated metabolic syndrome: mechanistic links*  
456 *to chronic kidney disease*. Clinical Journal of the American Society of Nephrology, 2007. **2**(3): p.  
457 550-562.
- 458 3. Thompson, W.G., et al. *Treatment of obesity*. in *Mayo Clinic Proceedings*. 2007. Elsevier.
- 459 4. Avgerinos, K.I., et al., *Obesity and cancer risk: Emerging biological mechanisms and perspectives*.  
460 2019. **92**: p. 121-135.
- 461 5. Alford, S., et al., *Obesity as a risk factor for Alzheimer's disease: weighing the evidence*. 2018.  
462 **19**(2): p. 269-280.
- 463 6. Han, T.S. and M.E. Lean, *A clinical perspective of obesity, metabolic syndrome and cardiovascular*  
464 *disease*. JRSM cardiovascular disease, 2016. **5**: p. 2048004016633371.
- 465 7. Crovesy, L., D. Masterson, and E.L.J.E.j.o.c.n. Rosado, *Profile of the gut microbiota of adults with*  
466 *obesity: a systematic review*. 2020. **74**(9): p. 1251-1262.
- 467 8. Stanislawski, M.A., et al., *Gut microbiota phenotypes of obesity*. 2019. **5**(1): p. 1-9.
- 468 9. Benahmed, A.G., et al., *Association between the gut and oral microbiome with obesity*. 2021. **70**:  
469 p. 102248.
- 470 10. El Kaoutari, A., et al., *The abundance and variety of carbohydrate-active enzymes in the human*  
471 *gut microbiota*. 2013. **11**(7): p. 497-504.
- 472 11. Turnbaugh, P.J., et al., *An obesity-associated gut microbiome with increased capacity for energy*  
473 *harvest*. nature, 2006. **444**(7122): p. 1027-131.
- 474 12. Jumbo-Lucioni, P., et al., *Systems genetics analysis of body weight and energy metabolism traits*  
475 *in Drosophila melanogaster*. BMC genomics, 2010. **11**(1): p. 297.
- 476 13. Shortt, C., et al., *Systematic review of the effects of the intestinal microbiota on selected*  
477 *nutrients and non-nutrients*. 2018. **57**(1): p. 25-49.
- 478 14. LeBlanc, J.G., et al., *Bacteria as vitamin suppliers to their host: a gut microbiota perspective*.  
479 2013. **24**(2): p. 160-168.
- 480 15. Overby, H.B. and J.F.J.C.H.R. Ferguson, *Gut microbiota-derived short-chain fatty acids facilitate*  
481 *microbiota: host cross talk and modulate obesity and hypertension*. 2021. **23**(2): p. 1-10.
- 482 16. Mohammadkhan, A.I., et al., *Development of the gut microbiome in children, and lifetime*  
483 *implications for obesity and cardiometabolic disease*. 2018. **5**(12): p. 160.
- 484 17. Kimura, I., et al., *The gut microbiota suppresses insulin-mediated fat accumulation via the short-*  
485 *chain fatty acid receptor GPR43*. Nature communications, 2013. **4**: p. 1829.
- 486 18. Tilg, H. and A.R. Moschen, *Gut Microbiome, Obesity, and Metabolic Syndrome*. Metabolic  
487 Syndrome: A Comprehensive Textbook, 2016: p. 447-459.
- 488 19. Bindels, L.B., E.M. Dewulf, and N.M.J.T.i.p.s. Delzenne, *GPR43/FFA2: physiopathological*  
489 *relevance and therapeutic prospects*. 2013. **34**(4): p. 226-232.
- 490 20. Davison, J.M., et al., *Microbiota regulate intestinal epithelial gene expression by suppressing the*  
491 *transcription factor Hepatocyte nuclear factor 4 alpha*. Genome Research, 2017: p. gr.  
492 220111.116.
- 493 21. Ye, J., et al., *Influences of the gut microbiota on DNA methylation and histone modification*.  
494 2017. **62**(5): p. 1155-1164.
- 495 22. Fellows, R., et al., *Microbiota derived short chain fatty acids promote histone crotonylation in the*  
496 *colon through histone deacetylases*. 2018. **9**(1): p. 1-15.
- 497 23. Tilg, H., A.R. Moschen, and A.J.G. Kaser, *Obesity and the microbiota*. 2009. **136**(5): p. 1476-1483.

- 498 24. Si, J., et al., *Oral microbiota: microbial biomarkers of metabolic syndrome independent of host*  
499 *genetic factors*. 2017. **7**: p. 516.
- 500 25. Araujo, D.S., et al., *Salivary Microbiological and Gingival Health Status Evaluation of Adolescents*  
501 *With Overweight and Obesity: A Cluster Analysis*. 2020. **8**: p. 429.
- 502 26. de Andrade, P.A.M., et al., *Shifts in the bacterial community of saliva give insights on the*  
503 *relationship between obesity and oral microbiota in adolescents*. 2020. **202**(5): p. 1085-1095.
- 504 27. Raju, S.C., et al., *Gender-specific associations between saliva microbiota and body size*. 2019. **10**:  
505 p. 767.
- 506 28. Schacher, B., et al., *Aggregatibacter actinomycetemcomitans as indicator for aggressive*  
507 *periodontitis by two analysing strategies*. 2007. **34**(7): p. 566-573.
- 508 29. Balakrishnan, B., et al., *Ethnic variability associating gut and oral microbiome with obesity in*  
509 *children*. 2021. **13**(1): p. 1-15.
- 510 30. Szafranski, S.P., et al., *Functional biomarkers for chronic periodontitis and insights into the roles*  
511 *of Prevotella nigrescens and Fusobacterium nucleatum; a metatranscriptome analysis*. 2015.  
512 **1**(1): p. 1-13.
- 513 31. Janem, W.F., et al., *Salivary inflammatory markers and microbiome in normoglycemic lean and*  
514 *obese children compared to obese children with type 2 diabetes*. 2017. **12**(3): p. e0172647.
- 515 32. Sohail, M.U., et al., *Profiling the oral microbiome and plasma biochemistry of obese*  
516 *hyperglycemic subjects in Qatar*. 2019. **7**(12): p. 645.
- 517 33. Azad, M., et al., *Probiotic species in the modulation of gut microbiota: an overview*. 2018. **2018**.
- 518 34. Khalili, L., et al., *The effects of lactobacillus casei on glycemic response, serum sirtuin1 and*  
519 *fetuin-a levels in patients with type 2 diabetes mellitus: a randomized controlled trial*. 2019.  
520 **23**(1): p. 68.
- 521 35. Million, M., et al., *Comparative meta-analysis of the effect of Lactobacillus species on weight*  
522 *gain in humans and animals*. 2012. **53**(2): p. 100-108.
- 523 36. Thommes, M., et al., *Designing metabolic division of labor in microbial communities*. 2019. **4**(2):  
524 p. e00263-18.
- 525 37. Estrela, S., J.J. Morris, and B.J.E.m. Kerr, *Private benefits and metabolic conflicts shape the*  
526 *emergence of microbial interdependencies*. 2016. **18**(5): p. 1415-1427.
- 527 38. Zomorodi, A.R. and D.J.N.c. Segrè, *Genome-driven evolutionary game theory helps understand*  
528 *the rise of metabolic interdependencies in microbial communities*. 2017. **8**(1): p. 1-12.
- 529 39. Morris, J.J.J.T.i.G., *Black Queen evolution: the role of leakiness in structuring microbial*  
530 *communities*. 2015. **31**(8): p. 475-482.
- 531 40. Bagheri, M., et al., *A metabolome and microbiome wide association study of healthy eating*  
532 *index points to the mechanisms linking dietary pattern and metabolic status*. 2021: p. 1-15.
- 533 41. Ferguson, L.V., et al., *Seasonal shifts in the insect gut microbiome are concurrent with changes in*  
534 *cold tolerance and immunity*. *Functional Ecology*, 2018. **32**(10): p. 2357-2368.
- 535 42. Tang, Z.-Z., et al., *Multi-omic analysis of the microbiome and metabolome in healthy subjects*  
536 *reveals microbiome-dependent relationships between diet and metabolites*. 2019. **10**: p. 454.
- 537 43. Team, R.C. and R.J.U.h.w.R.-p.o. DC, *A language and environment for statistical computing.*  
538 *Vienna, Austria: R Foundation for Statistical Computing; 2012*. 2019.
- 539 44. Callahan, B.J., et al., *DADA2: high-resolution sample inference from Illumina amplicon data*.  
540 2016. **13**(7): p. 581-583.
- 541 45. Quast, C., et al., *The SILVA ribosomal RNA gene database project: improved data processing and*  
542 *web-based tools*. 2012. **41**(D1): p. D590-D596.
- 543 46. Paulson, J.N., et al., *Differential abundance analysis for microbial marker-gene surveys*. 2013.  
544 **10**(12): p. 1200-1202.

- 545 47. Oksanen, J., et al., *vegan: community ecology package. R package version 1.15-4. R Foundation*  
546 *for Statistical Computing, Vienna, Austria.* 2009.
- 547 48. Paradis, E., J. Claude, and K.J.B. Strimmer, *APE: analyses of phylogenetics and evolution in R*  
548 *language.* 2004. **20**(2): p. 289-290.
- 549 49. Schliep, K.P., *Estimating phylogenetic trees with phangorn.* 2019.
- 550 50. Schliep, K.P.J.B., *phangorn: phylogenetic analysis in R.* 2011. **27**(4): p. 592-593.
- 551 51. McMurdie, P.J. and S.J.P.o. Holmes, *phyloseq: an R package for reproducible interactive analysis*  
552 *and graphics of microbiome census data.* 2013. **8**(4): p. e61217.
- 553 52. Douglas, G.M., et al., *PICRUSt2 for prediction of metagenome functions.* 2020. **38**(6): p. 685-688.
- 554 53. Kanehisa, M. and S.J.N.a.r. Goto, *KEGG: kyoto encyclopedia of genes and genomes.* 2000. **28**(1):  
555 p. 27-30.
- 556 54. Karp, P.D., et al., *The metacyc database.* 2002. **30**(1): p. 59-61.
- 557 55. Bairoch, A.J.N.a.r., *The ENZYME database in 2000.* 2000. **28**(1): p. 304-305.
- 558 56. Gloor, G.J.A.m.m., *ALDEx2: ANOVA-Like Differential Expression tool for compositional data.*  
559 *2015.* **20**: p. 1-11.
- 560 57. Kassambara, A.J.F.h.m.m.c.w.p.r.i.h., *Pipe-Friendly Framework for Basic Statistical Tests [R*  
561 *Package Rstatix Version 0.7. 0].* 2021.
- 562 58. Venables, W. and B. Ripley, *Random and mixed effects, in Modern applied statistics with S.* 2002,  
563 Springer. p. 271-300.
- 564 59. Kassambara, A. and M.A. Kassambara, *Package 'ggpubr'.* 2020.
- 565 60. Wickham, H., *ggplot2: elegant graphics for data analysis.* 2016: springer.
- 566 61. Harrell Jr, F.E. and M.F.E.J.C. Harrell Jr, *Package 'hmisc'.* 2019. **2019**: p. 235-6.
- 567 62. Kuhn, M., S. Jackson, and J.J.R.P.v. Cimentada, *corr: Correlations in R.* 2020. **2**.
- 568 63. Kindt, R. and R. Coe, *Tree diversity analysis: a manual and software for common statistical*  
569 *methods for ecological and biodiversity studies.* 2005: World Agroforestry Centre.
- 570 64. Bombin, A., L.K.J.E. Reed, and evolution, *The changing biodiversity of Alabama Drosophila:*  
571 *important impacts of seasonal variation, urbanization, and invasive species.* 2016. **6**(19): p.  
572 7057-7069.
- 573 65. Leboffe, M.J. and B.E. Pierce, *Microbiology: laboratory theory and application.* 2012: Morton  
574 Publishing Company.
- 575 66. Dhariwal, A., et al., *MicrobiomeAnalyst: a web-based tool for comprehensive statistical, visual*  
576 *and meta-analysis of microbiome data.* 2017. **45**(W1): p. W180-W188.
- 577 67. Wu, H., V. Tremaroli, and F. Bäckhed, *Linking microbiota to human diseases: a systems biology*  
578 *perspective.* Trends in Endocrinology & Metabolism, 2015. **26**(12): p. 758-770.
- 579 68. Bruce-Keller, A.J., et al., *Obese-type gut microbiota induce neurobehavioral changes in the*  
580 *absence of obesity.* 2015. **77**(7): p. 607-615.
- 581 69. Jehrke, L., et al., *The impact of genome variation and diet on the metabolic phenotype and*  
582 *microbiome composition of Drosophila melanogaster.* Scientific reports, 2018. **8**(1): p. 1-15.
- 583 70. Pawitan, Y., et al., *False discovery rate, sensitivity and sample size for microarray studies.* 2005.  
584 **21**(13): p. 3017-3024.
- 585 71. Bombin, A., et al., *Influence of Lab Adapted Natural Diet and Microbiota on Life History and*  
586 *Metabolic Phenotype of Drosophila melanogaster.* 2020. **8**(12): p. 1972.
- 587 72. Althouse, A.D. and P. Soman, *Understanding the true significance of a P value.* 2017, Springer.
- 588 73. Palmas, V., et al., *Gut microbiota markers associated with obesity and overweight in Italian*  
589 *adults.* 2021. **11**(1): p. 1-14.
- 590 74. Del Chierico, F., et al., *Gut microbiota markers in obese adolescent and adult patients: age-*  
591 *dependent differential patterns.* 2018. **9**: p. 1210.



- 592 75. Durbán, A., et al., *Effect of dietary carbohydrate restriction on an obesity-related prevotella-*  
593 *dominated human fecal microbiota*. 2013. **2**(235722).
- 594 76. Mashima, I., et al., *The distribution and frequency of oral Veillonella spp. associated with chronic*  
595 *periodontitis*. 2015. **4**(3): p. 150-160.
- 596 77. Maciel, S.S., et al., *Does obesity influence the subgingival microbiota composition in periodontal*  
597 *health and disease?* 2016. **43**(12): p. 1003-1012.
- 598 78. Kim, Y.J., et al., *The Gut/Lung Microbiome Axis in Obesity, Asthma, and Bariatric Surgery: A*  
599 *Literature Review*. 2021. **29**(4): p. 636-644.
- 600 79. Huang, Y.J., et al., *The airway microbiome in patients with severe asthma: associations with*  
601 *disease features and severity*. 2015. **136**(4): p. 874-884.
- 602 80. Lee, K.-C., D.Y. Kil, and W.J.J.J.o.M. Sul, *Cecal microbiome divergence of broiler chickens by sex*  
603 *and body weight*. 2017. **55**(12): p. 939-945.
- 604 81. Xie, G., et al., *Distinctly altered gut microbiota in the progression of liver disease*. 2016. **7**(15): p.  
605 19355.
- 606 82. Henning, S.M., et al., *Decaffeinated green and black tea polyphenols decrease weight gain and*  
607 *alter microbiome populations and function in diet-induced obese mice*. 2018. **57**(8): p. 2759-  
608 2769.
- 609 83. Krishnan, K., T. Chen, and B.J.O.d. Paster, *A practical guide to the oral microbiome and its*  
610 *relation to health and disease*. 2017. **23**(3): p. 276-286.
- 611 84. Toyama, N., et al., *Comprehensive Analysis of Risk Factors for Periodontitis Focusing on the*  
612 *Saliva Microbiome and Polymorphism*. 2021. **18**(12): p. 6430.
- 613 85. Salah, M., et al., *New insights on obesity and diabetes from gut microbiome alterations in*  
614 *Egyptian adults*. 2019. **23**(10): p. 477-485.
- 615 86. Schroeder, B.O., et al., *Obesity-associated microbiota contributes to mucus layer defects in*  
616 *genetically obese mice*. 2020. **295**(46): p. 15712-15726.
- 617 87. Liu, J.-P., et al., *Effects of different diets on intestinal microbiota and nonalcoholic fatty liver*  
618 *disease development*. 2016. **22**(32): p. 7353.
- 619 88. Del Chierico, F., et al., *Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and*  
620 *obese patients unveiled by an integrated meta-omics-based approach*. 2017. **65**(2): p. 451-464.
- 621 89. Peters, B.A., et al., *A taxonomic signature of obesity in a large study of American adults*. 2018.  
622 **8**(1): p. 1-13.
- 623 90. Uberos, J., et al., *Overweight and obesity as risk factors for the asymptomatic carrier state of*  
624 *Neisseria meningitidis among a paediatric population*. 2010. **29**(3): p. 333-334.
- 625 91. Zhang, Q., et al., *Comparison of gut microbiota between adults with autism spectrum disorder*  
626 *and obese adults*. 2021. **9**: p. e10946.
- 627 92. Moreno-Indias, I., et al., *Insulin resistance is associated with specific gut microbiota in appendix*  
628 *samples from morbidly obese patients*. 2016. **8**(12): p. 5672.
- 629 93. Haffajee, A.D. and S.S.J.J.o.c.p. Socransky, *Relation of body mass index, periodontitis and*  
630 *Tannerella forsythia*. 2009. **36**(2): p. 89-99.
- 631 94. Silva-Boghossian, C.M., et al., *Subgingival microbial profile of obese women with periodontal*  
632 *disease*. 2018. **89**(2): p. 186-194.
- 633 95. Belstrøm, D.J.J.o.o.m., *The salivary microbiota in health and disease*. 2020. **12**(1): p. 1723975.
- 634 96. Thomas, C., et al., *Obesity Drives an Oral Microbiota Signature of Female Patients with*  
635 *Periodontitis: A Pilot Study*. 2021. **11**(5): p. 745.
- 636 97. Kwek, H., M. Wilson, and H.J.J.o.c.p. Newman, *Mycoplasma in relation to gingivitis and*  
637 *periodontitis*. 1990. **17**(2): p. 119-122.
- 638 98. Nóvoa, L., et al., *The Subgingival Microbiome in Patients with Down Syndrome and Periodontitis*.  
639 2020. **9**(8): p. 2482.

- 640 99. Nardelli, C., et al., *Characterization of the duodenal mucosal microbiome in obese adult subjects*  
641 *by 16S rRNA sequencing*. 2020. **8**(4): p. 485.
- 642 100. Kang, Y., et al., *Konjaku flour reduces obesity in mice by modulating the composition of the gut*  
643 *microbiota*. 2019. **43**(8): p. 1631-1643.
- 644 101. Federico, A., et al., *Gastrointestinal hormones, intestinal microbiota and metabolic homeostasis*  
645 *in obese patients: effect of bariatric surgery*. 2016. **30**(3): p. 321-330.
- 646 102. Jang, H.B., et al., *Association of dietary patterns with the fecal microbiota in Korean adolescents*.  
647 2017. **3**(1): p. 1-11.
- 648 103. Precup, G. and D.-C.J.B.J.o.N. Vodnar, *Gut Prevotella as a possible biomarker of diet and its*  
649 *eubiotic versus dysbiotic roles: a comprehensive literature review*. 2019. **122**(2): p. 131-140.
- 650 104. Ding, Q., et al., *Liupao tea extract alleviates diabetes mellitus and modulates gut microbiota in*  
651 *rats induced by streptozotocin and high-fat, high-sugar diet*. 2019. **118**: p. 109262.
- 652 105. Vojinovic, D., et al., *Relationship between gut microbiota and circulating metabolites in*  
653 *population-based cohorts*. 2019. **10**(1): p. 1-7.
- 654 106. Tang, S., et al., *Screening of microbes associated with swine growth and fat deposition traits*  
655 *across the intestinal tract*. 2020. **11**: p. 2475.
- 656 107. Gaukroger, C.H., et al., *Changes in faecal microbiota profiles associated with performance and*  
657 *birthweight of piglets*. 2020. **11**: p. 917.
- 658 108. Zeng, H., et al., *Colonic inflammation accompanies an increase of  $\beta$ -catenin signaling and*  
659 *Lachnospiraceae/Streptococcaceae bacteria in the hind gut of high-fat diet-fed mice*. 2016. **35**: p.  
660 30-36.
- 661 109. Liu, S., P. Qin, and J.J.M. Wang, *High-fat diet alters the intestinal microbiota in streptozotocin-*  
662 *induced type 2 diabetic mice*. 2019. **7**(6): p. 176.
- 663 110. Lee, P.S., et al., *Garcinol reduces obesity in high-fat-diet-fed mice by modulating gut microbiota*  
664 *composition*. 2019. **63**(2): p. 1800390.
- 665 111. Calderón-Pérez, L., et al., *Gut metagenomic and short chain fatty acids signature in*  
666 *hypertension: A cross-sectional study*. 2020. **10**(1): p. 1-16.
- 667 112. Yang, M., et al., *Beneficial Effects of Newly Isolated Akkermansia muciniphila Strains from the*  
668 *Human Gut on Obesity and Metabolic Dysregulation*. 2020. **8**(9): p. 1413.
- 669 113. McMurray, F., D.A. Patten, and M.E.J.O. Harper, *Reactive oxygen species and oxidative stress in*  
670 *obesity—recent findings and empirical approaches*. 2016. **24**(11): p. 2301-2310.
- 671 114. Yanoff, L., et al., *Inflammation and iron deficiency in the hypoferremia of obesity*. 2007. **31**(9): p.  
672 1412-1419.
- 673 115. Du Clos, T.W.J.A.o.m., *Function of C-reactive protein*. 2000. **32**(4): p. 274-278.
- 674 116. Via, M.J.I.S.R.N., *The malnutrition of obesity: micronutrient deficiencies that promote diabetes*.  
675 2012. **2012**.
- 676 117. Hernandez, D.J., et al., *Environmental stress destabilizes microbial networks*. 2021. **15**(6): p.  
677 1722-1734.
- 678 118. Li, H., et al., *Shifting species interaction in soil microbial community and its influence on*  
679 *ecosystem functions modulating*. 2013. **65**(3): p. 700-708.
- 680 119. Hammarlund, S.P. and W.R.J.P.o.t.N.A.o.S. Harcombe, *Refining the stress gradient hypothesis in*  
681 *a microbial community*. 2019. **116**(32): p. 15760-15762.
- 682 120. Lu, T., et al., *Understanding the influence of glyphosate on the structure and function of*  
683 *freshwater microbial community in a microcosm*. 2020. **260**: p. 114012.
- 684 121. Ghosh, T.S., et al., *Gut microbiomes of Indian children of varying nutritional status*. 2014. **9**(4): p.  
685 e95547.
- 686 122. Chattopadhyay, S., et al., *Artificial sweeteners—a review*. 2014. **51**(4): p. 611-621.
- 687 123. Pasha, I., et al., *Effect of dietetic sweeteners on the quality of cookies*. 2002. **4**(2): p. 245-248.

- 688 124. Gultekin, F., et al., *Food additives and microbiota*. 2020. **7**(2): p. 192.
- 689 125. Söderling, E. and K.J.A.O.S. Pienihäkkinen, *Effects of xylitol and erythritol consumption on*  
690 *mutans streptococci and the oral microbiota: a systematic review*. 2020. **78**(8): p. 599-608.
- 691 126. Larsen, N., et al., *Potential of pectins to beneficially modulate the gut microbiota depends on*  
692 *their structural properties*. 2019. **10**: p. 223.
- 693 127. Jiang, T., et al., *Apple-derived pectin modulates gut microbiota, improves gut barrier function,*  
694 *and attenuates metabolic endotoxemia in rats with diet-induced obesity*. 2016. **8**(3): p. 126.
- 695 128. Carrera-Quintanar, L., et al., *Phytochemicals that influence gut microbiota as prophylactics and*  
696 *for the treatment of obesity and inflammatory diseases*. 2018. **2018**.
- 697 129. Makki, K., et al., *The impact of dietary fiber on gut microbiota in host health and disease*. 2018.  
698 **23**(6): p. 705-715.
- 699 130. Kanehisa, M.J.P.S., *Toward understanding the origin and evolution of cellular organisms*. 2019.  
700 **28**(11): p. 1947-1951.
- 701 131. Park, J.A., et al., *Anti-obesity effect of kimchi fermented with *W eissella koreensis* OK 1-6 as*  
702 *starter in high-fat diet-induced obese C57 BL/6J mice*. 2012. **113**(6): p. 1507-1516.
- 703 132. Kalogeropoulou, D., et al., *Lysine ingestion markedly attenuates the glucose response to ingested*  
704 *glucose without a change in insulin response*. 2009. **90**(2): p. 314-320.
- 705 133. Ren, W., et al., *Glutamine metabolism in macrophages: a novel target for obesity/type 2*  
706 *diabetes*. 2019. **10**(2): p. 321-330.
- 707 134. Abboud, K.Y., et al., *Oral glutamine supplementation reduces obesity, pro-inflammatory*  
708 *markers, and improves insulin sensitivity in DIO wistar rats and reduces waist circumference in*  
709 *overweight and obese humans*. 2019. **11**(3): p. 536.
- 710 135. Arnoriaga-Rodríguez, M., et al., *Obesity-associated deficits in inhibitory control are phenocopied*  
711 *to mice through gut microbiota changes in one-carbon and aromatic amino acids metabolic*  
712 *pathways*. 2021.
- 713 136. Christensen, K.E., et al., *Steatosis in mice is associated with gender, folate intake, and expression*  
714 *of genes of one-carbon metabolism*. 2010. **140**(10): p. 1736-1741.
- 715 137. Furukawa, S., et al., *Increased oxidative stress in obesity and its impact on metabolic syndrome*.  
716 2017. **114**(12): p. 1752-1761.
- 717 138. Rochette, L., et al., *Direct and indirect antioxidant properties of  $\alpha$ -lipoic acid and therapeutic*  
718 *potential*. 2013. **57**(1): p. 114-125.
- 719 139. Allam-Ndoul, B., et al., *Associations between branched chain amino acid levels, obesity and*  
720 *cardiometabolic complications*. 2015. **1**(5): p. 157-162.
- 721 140. Syed Ikmal, S.I.Q., et al., *Potential biomarkers of insulin resistance and atherosclerosis in type 2*  
722 *diabetes mellitus patients with coronary artery disease*. 2013. **2013**.
- 723 141. Gall, W.E., et al.,  *$\alpha$ -Hydroxybutyrate is an early biomarker of insulin resistance and glucose*  
724 *intolerance in a nondiabetic population*. 2010. **5**(5): p. e10883.
- 725 142. Pardo, F., et al., *Molecular implications of adenosine in obesity*. 2017. **55**: p. 90-101.
- 726 143. Panagiotou, C., et al., *Effect of steviol, steviol glycosides and stevia extract on glucocorticoid*  
727 *receptor signaling in normal and cancer blood cells*. 2018. **460**: p. 189-199.


728

729

730

731

732 TABLES AND FIGURES



733

734

735 **Figure 1: Obesity groups can be discriminated by the abundance of salivary or fecal**

736 **microbiota.** Linear discriminant analysis of A) ASVs identified in salivary samples B) ASVs

737 identified in fecal samples. ASVs with abundance of less than 20 sequences were filtered out.

738 Obesity groups are represented by color, lean group by red, overweight group by green, and

739 obese group by blue. Confidence ellipses are shaded. Normal data ellipses are unfilled and

740 leveled to include 50% of the samples.

741


742

743

744

745

746



747

748

**Figure 2: Obese and lean groups can be characterized by the abundance of**

749

**dominant bacteria genera.** Linear discriminant analysis of the 15 most abundant bacterial

750

genera identified in A) Salivary samples B) Fecal Samples. Obesity groups are represented by

751

color, lean group by red, overweight group by green, and obese group by blue. The higher

752

abundance of bacterial genera in the obesity groups is indicated by the direction of the vector

753

rays. The intensity of vector rays' color corresponds to the strength of the impact. Confidence

754

ellipses are shaded. Normal data ellipses are unfilled and leveled to include 50% of the samples.

755


756

757


758

759

760



761 **Figure 3: Number of strong connections between bacterial genera increases with the**  
 762 **obesity status.** Spearman's rank correlation network between A) Salivary bacterial genera of  
 763 lean individuals; B) Salivary bacterial genera of overweight individuals; C) Salivary bacterial  
 764 genera of obese individuals; D) Fecal bacterial genera of lean individuals; E) Fecal bacterial  
 765 genera of overweight individuals; F) Fecal bacterial genera of obese individuals. For A-C  
 766 included genera had minimum abundance of 30 sequences and for D-F minimum abundance of  
 767 20 sequences.



768

769

770 **Figure 4: Obesity groups can be discriminated by metabolic potential predicted by**

771 **PICRUSt2.** Linear discriminant analysis of relative abundances of A) ECs inferred from saliva

772 samples B) KOs inferred from saliva samples, C) MetaCyc pathways inferred from saliva

773 samples, D) ECs inferred from fecal samples, E) KOs inferred from fecal samples, F) MetaCyc

774 pathways inferred from fecal samples. Obesity groups are represented by color, lean group by

775 red, overweight group by green, and obese group by blue. Confidence ellipses are shaded.

776 Normal data ellipses are unfilled and leveled to include 50% of the samples.

777

778

779

780 **Supplementary Figures' Legends**

781 **Supplement figure 1: Obesity groups could be characterized based on abundance of**  
782 **salivary bacterial taxa, especially at lower taxonomic ranks.** Linear discriminant analysis of  
783 A) bacterial species, B) bacterial families, C) bacterial families, D) bacterial orders, E) bacterial  
784 classes F) bacterial phyla. Taxa with abundance of less than 20 sequences were filtered out.  
785 Obesity groups are represented by color, lean group by red, overweight group by green, and  
786 obese group by blue. Confidence ellipses are shaded. Normal data ellipses are unfilled and  
787 leveled to include 50% of the samples.

788 **Supplement figure 2: Obesity groups could be characterized based on abundance of fecal**  
789 **bacterial taxa, especially at lower taxonomic ranks.** Linear discriminant analysis of A)  
790 bacterial species, B) bacterial genera, C) bacterial families, D) bacterial orders, E) bacterial  
791 classes F) bacterial phyla. Taxa with abundance of less than 20 sequences were filtered out.  
792 Obesity groups are represented by color, lean group by red, overweight group by green, and  
793 obese group by blue. Confidence ellipses are shaded. Normal data ellipses are unfilled and  
794 leveled to include 50% of the samples.

795 **Supplement figure 3: Lean and obese groups can be characterized by the abundance of**  
796 **dominant salivary bacterial taxa, across most taxonomic ranks.** The results also indicate that  
797 the most abundant bacteria taxa are not the most influential for characterization of obesity  
798 groups. Linear discriminant analysis of 15 most abundant salivary bacterial A) Species, B)  
799 Families, C) Orders, D) Classes. Obesity groups are represented by color, lean group by red,  
800 overweight group by green, and obese group by blue. The intensity of vector rays' color  
801 corresponds to the strength of the impact. Confidence ellipses are shaded. Normal data ellipses  
802 are unfilled and leveled to include 50% of the samples.



803 **Supplement figure 4: Lean and obese groups can be characterized by the abundance of**  
804 **dominant fecal bacterial taxa across most taxonomic ranks.** The results also indicate that  
805 most abundant bacteria taxa are not the most influential for characterization of obesity groups.  
806 Linear discriminant analysis of 15 most abundant fecal bacteria A) Species, B) Families, C)  
807 Orders, D) Classes. Obesity groups are represented by color, lean group by red, overweight  
808 group by green, and obese group by blue. The intensity of vector rays' color corresponds to the  
809 strength of the impact. Confidence ellipses are shaded. Normal data ellipses are unfilled and  
810 leveled to include 50% of the samples.

#### 811 **Supplementary Tables' Legends**

812 **Supplement Table 1: Salivary but not fecal samples exhibited a significant difference in**  
813 **compositional and phylogenetic distances between lean and obese groups.** Pairwise  
814 comparisons of Bray-Curtis, Weighted and Unweighted Unifrac distances between obesity  
815 groups in salivary and fecal samples.

816 **Supplement Table 2: Obesity groups did not exhibit a significant variation in alpha**  
817 **diversity indices of salivary and fecal microbial communities.** Pairwise comparisons of  
818 Shannon and Gini-Simpson indices', as well as species richness values between obesity groups  
819 in salivary and fecal samples.

820 **Supplement Table 3: More salivary bacterial taxa exhibited a significant difference in their**  
821 **abundances between obesity group than fecal bacterial taxa.** Pairwise comparisons of  
822 microbiota taxa abundances between obesity groups in A) salivary samples and B) fecal samples.

823 **Supplement Table 4: The number of strong correlations between bacterial taxa in salivary**  
824 **and fecal samples increased with the increase of the obesity status of the host.** Pairwise

825 comparisons of absolute values for inter-bacterial correlation coefficients between obesity  
826 groups.

827 **Supplement Table 5: More of the recently consumed nutrients produce a significant effect**  
828 **on compositional and phylogenetic diversity distances of salivary samples than on fecal**  
829 **samples.** The impact of changes in recently consumed nutrients on Bray-Curtis and Weighted  
830 and Unweighted Unifrac distances of salivary and fecal samples. Sq stands for quadratic effect  
831 of the nutrient on beta diversity distances.

832 **Supplement Table 6: More of the habitually consumed nutrients produce a significant**  
833 **effect on compositional and phylogenetic diversity distances of fecal samples than on**  
834 **salivary samples.** The impact of changes in habitually consumed nutrients on Bray-Curtis and  
835 Weighted and Unweighted Unifrac distances of salivary and fecal samples. Sq stands for  
836 quadratic effect of the nutrient on beta diversity distances.

837 **Supplement Table 7: Predicted metabolic potential of bacterial community varies between**  
838 **obesity groups.** Pairwise comparisons of predicted bacterial enzymes, Kegg orthologs, and  
839 MetaCyc abundances between obesity groups in A) salivary samples and B) fecal samples. ECs,  
840 KOs, and MetaCyc pathways that were not significantly different ( $p > 0.05$ ) between obesity  
841 groups were excluded from the table.

842 **Supplement table 8: Some of the predicted bacterial metabolic pathways are uniquely**  
843 **enriched in obesity groups.** Pairwise comparisons of uniquely enriched bacterial metabolic  
844 pathways identified from salivary and fecal samples between obesity groups.

845 **Supplement table 9: Predicted bacterial metabolic potential influences plasma and stool**  
846 **metabolites concentrations.** The effect of A) ECs identified from salivary samples on plasma

847 metabolites concentrations, B) ECs identified from salivary samples on stool metabolites  
848 concentrations, C) ECs identified from fecal samples on plasma metabolites concentrations, D)  
849 ECs identified from fecal samples on stool metabolites concentrations, E) KOs identified from  
850 salivary samples on plasma metabolites concentrations, F) KOs identified from salivary samples  
851 on stool metabolites concentrations, G) KOs identified from fecal samples on plasma metabolites  
852 concentrations, H) KOs identified from fecal samples on stool metabolites concentrations, I)  
853 MetaCyc pathways identified from salivary samples on plasma metabolites concentrations, J)  
854 MetaCyc pathways identified from salivary samples on stool metabolites concentrations, K)  
855 MetaCyc pathways identified from fecal samples on plasma metabolites concentrations, L)  
856 MetaCyc pathways identified from fecal samples on stool metabolites concentrations.

857